Extended-release niacin raises HDL and lowers triglycerides and Lp(a), but the AIM-HIGH and HPS2-THRIVE trials found no additional cardiovascular benefit when added to statin therapy, leading to near-complete abandonment of niacin for atherosclerosis.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.